146 related articles for article (PubMed ID: 38746066)
1. Hydroxychloroquine and the associated risk of arrhythmias.
Farhat H; Kassab CJ; Tlaiss Y; Gutlapalli SD; Ganipineni VDP; Paramsothy J; Tedesco S; Kailayanathan T; Abdulaal R; Otterbeck P
Glob Cardiol Sci Pract; 2024 Mar; 2024(2):e202417. PubMed ID: 38746066
[TBL] [Abstract][Full Text] [Related]
2. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
Lo CH; Wei JC; Wang YH; Tsai CF; Chan KC; Li LC; Lo TH; Su CH
Front Immunol; 2021; 12():631869. PubMed ID: 33868251
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
Nirk EL; Reggiori F; Mauthe M
EMBO Mol Med; 2020 Aug; 12(8):e12476. PubMed ID: 32715647
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Dima A; Jurcut C; Arnaud L
Joint Bone Spine; 2021 May; 88(3):105143. PubMed ID: 33515791
[TBL] [Abstract][Full Text] [Related]
7. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.
Chen CY; Wang FL; Lin CC
Clin Toxicol (Phila); 2006; 44(2):173-5. PubMed ID: 16615675
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
[TBL] [Abstract][Full Text] [Related]
9. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
[TBL] [Abstract][Full Text] [Related]
10. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Desmarais J; Rosenbaum JT; Costenbader KH; Ginzler EM; Fett N; Goodman S; O'Dell J; Pineau CA; Schmajuk G; Werth VP; Link MS; Kovacs R
Arthritis Rheumatol; 2021 Dec; 73(12):2151-2160. PubMed ID: 34697918
[TBL] [Abstract][Full Text] [Related]
11. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
Khan AA; Khan Z
Chem Biol Interact; 2020 Dec; 332():109299. PubMed ID: 33098839
[TBL] [Abstract][Full Text] [Related]
12. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
13. Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
Hoque MR; Lu L; Daftarian N; Esdaile JM; Xie H; Aviña-Zubieta JA
Arthritis Rheumatol; 2023 Mar; 75(3):475-484. PubMed ID: 36054570
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
15. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Fairley JL; Nikpour M; Mack HG; Brosnan M; Saracino AM; Pellegrini M; Wicks IP
Intern Med J; 2023 Mar; 53(3):311-317. PubMed ID: 35969110
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxychloroquine treatment on QT interval.
Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
20. QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Nishiyama T; Kondo Y; Tsuboi H; Noma H; Tabuchi D; Sugita T; Okamoto S; Terasaki T; Shimizu M; Honda F; Ohyama A; Kurata I; Yagishita M; Abe S; Takahashi H; Osada A; Hagiwara S; Matsumoto I; Sumida T
Mod Rheumatol; 2021 Nov; 31(6):1107-1112. PubMed ID: 33496215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
